PDCD1 and neoplasm: For instance, in brainstem glioma patients, the combination of the PD-1 inhibitor nivolumab with repeated radiotherapy has significantly improved overall survival, likely due to radiation-induced tumor antigen release that promotes immune cell infiltration into the tumor microenvironment (85, 86).